NEW YORK (360Dx) – Thermo Fisher Scientific disclosed in a recent regulatory filing that the aggregate purchase price for IntegenX was $65 million. In March, the company announced that it had acquired IntegenX, a developer of rapid DNA testing technology for forensics and human identification.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.